Dialysis Access Treatment Devices – Market Insights – Japan

The Japanese dialysis access treatment device market will decline modestly through 2035, driven by the decreased patient population requiring dialysis care due to high mortality following COVID-19 and infectious disease impact. Favorable clinical trial outcomes demonstrating the benefits of DCBs and covered stents for dialysis access maintenance will further support growth.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for dialysis access treatment devices in Japan from 2019 through 2035.

Recent M&A activities and new product launches will lead to shifts in market shares going forward.

How have shares for competitors in the Japanese dialysis access treatment device market shifted recently?

What acquisitions are positioning companies to enter high-growth segments?

How are competitors leveraging portfolio expansions to strengthen their market position?

How will emerging technologies introduce new competitive dynamics in the dialysis access device market, and which procedure groups will see the greatest impact from these new devices?

The relaunch of Ellipsys will impact competitor and market dynamics in Japan.

How will the Ellipsys relaunch affect the percutaneous AVF segment in Japan?

Who are the emerging competitors in the percutaneous AVF segment, and who will gain the first mover advantage in Japan?

Growth in the dialysis access maintenance device market will be supported by rising procedure volumes and increased use of premium-priced devices.

What impact will growing clinical evidence have on the adoption of premium-priced dialysis access maintenance devices?

How will covered stents and DCBs affect the dialysis access maintenance device segment?